Get the latest news on Nabriva Therapeutics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on NBRVF performance

Latest Nabriva Therapeutics Stock News | OTC:NBRVF | Benzinga

Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.

NABRIVA THERAPEUTICS NEW by Nabriva Therapeutics plc

Comments

Nabriva Therapeutics Stock News

News

Latest Nabriva Therapeutics Stock News | OTC:NBRVF | Benzinga

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga